Relationship between encapsulated drug particle size and initial release of recombinant human growth hormone from biodegradable microspheres

Journal of Pharmaceutical Sciences

Volumn 93, Issue 10, 2004, Pages 2624-2634

  Costantino, Henry R ^a,b   Johnson, Olufunmi L ^a   Zale, Stephen E ^a  

^a ALKERMES INC   (United States)

^b Nastech Pharmaceutical Company Inc   (United States)

Author keywords

Biodegradable polymers; Controlled release delivery; Initial release; Particle size; Poly(lactide co glycolide) (PLG) microspheres; Proteins; Recombinant human growth hormone (rhGH); Spray freeze drying

Indexed keywords

HUMAN GROWTH HORMONE; MICROSPHERE; POLYGLACTIN; ZINC CARBONATE;

AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; FLOW MEASUREMENT; FREEZE DRYING; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MICROENCAPSULATION; NEBULIZATION; NONHUMAN; PARTICLE SIZE; POWDER; RAT; SPRAY DRYING;

EID: 4844221183     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.20078     Document Type: Article

References (24)

1. Wang W. 1999. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int J Pharm 185:129-188.
2. Lai MC, Topp EM. 1999. Solid-state chemical stability of proteins and peptides. J Pharm Sci 88: 489-500.
3. Carpenter JF, Chang BS, Garzon-Rodriguez W, Randolph TW. 2002. Rational design of stable lyophilized protein formulations: Theory and practice. Pharm Biotechnol 13:109-133.
4. Veronese FM. 2001. Peptide and protein PEGylation: A review of problems and solutions. Biomaterials 22:405-417.
5. Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
6. Ergie JC, Browne JK. 2001. Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 84(Suppl 1):3-10.
7. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, Moody G, Zaritskaya LS, Sung C. 2002. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303:540-548.
8. Schwendeman SP, Cardamone M, Brandon MR, Klibanov AM, Langer R. 1996. Stability of proteins and their delivery from biodegradable polymer microspheres. In: Cohen S, Bernstien H, editors. Microparticulate systems for the delivery of proteins and vaccines. New York: Marcel Dekker. pp 1-49.
9. Burke PA, Putney SD. 1998. Improving protein therapeutics with sustained-release formulations. Nat Biotechnol 16:153-157.
10. Tracy MA, Ward KL, Firouzabadian L, Wang Y, Dong N, Qian R, Zhang Y. 1999. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials 20:1057-1062.
11. Johnson OL, Jaworowicz W, Cleland JL, Bailey L, Charnis M, Duenas E, Wu C, Shepard D, Magil S, Last T, Jones AJS, Putney SD. 1997. The stabilization of human growth hormone into biodegradable microspheres. Pharm Res 14:730-735.
12. Hebert P, Murphy K, Johnson O, Dong N, Jaworowicz W, Tracy MA, Cleland JL, Putney SD. 1998. A large-scale process to produce microencapsulated proteins. Pharm Res 15:357-361.
13. Costantino HR, Firouzabadian L, Hogeland K, Wu C, Beganski C, Carrasquillo KG, Cordova M, Griebenow K, Zale SE, Tracy MA. 2000. Protein spray-freeze drying. Effect of atomization conditions on particle size and stability. Pharm Res 17:1374-1383.
14. Costantino HR, Firouzabadian L, Wu C, Carrasquillo KG, Griebenow K, Zale SE, Tracy MA. 2002. Protein spray-freeze drying. 2. Effect of formulation variables on particle size and stability. J Pharm Sci 91:388-395.
15. Maa Y-F, Prestrelski SJ. 2000. Biopharmaceutical powers. Particle formation and formulation considerations. Curr Pharm Biotechnol 1:283-302.
16. Masters K. 1991. Spray drying handbook. New York: John Wiley and Sons.
17. Pikal MJ, Shah S, Senior D, Lang JE. 1983. Physical chemistry of freeze-drying. Measurement of sublimation rates for frozen aqueous solutions by a microbalance technique. J Pharm Sci 72:635-650.
18. Eckhart BM, Oeswein JQ, Bewley TA. 1991. Effect of freezing on aggregation of human growth hormone. Pharm Res 11:1360-1364.
19. Willemer H. 1992. Measurements of temperature, ice evaporation rates, and residual moisture contents in freeze drying. Dev Biol Stand 74:123-134.
20. Hsu CC, Nguyen HM, Yeung DA, Brooks DA, Koe GS, Bewley TA, Pearlman R. 1995. Surface denaturation at solid-void interface. A possible pathway by which opalescent particle form during storage of lyophilized tissue-type plasminogen activator at high temperatures. Pharm Res 12:69-77.
21. Dullien FAL. 1979. Porous media. Fluid transport and pore structure. New York: Academic Press.
22. Rhine WD, Hsieh DST, Langer R. 1980. Polymers for sustained macromolecule release: Procedures to fabricate reproducible delivery systems and control release kinetics. J Pharm Sci 69:265-270.
23. Siegel RA, Langer R. 1986. A new Monte-Carlo approach to diffusion in constricted porous geometries. J Colloid Interface Sci 109:426-440.
24. Wang J, Wang BM, Schwendeman SP. 2002. Characterization of the initial burst release of a model peptide from poly(D,L-lactide-co-glycolide) microspheres. J Control Release 82:289-307.